Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
VREX
$13.43
$0.19
Varex Imaging Corporation designs and manufactures X-ray imaging components. The company operates in two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components comprising X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, 3D reconstruction and computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers, and buckys. This segment's products are used in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy, oncology, CT, cardiac, surgery, dental, computer-aided detection, and other diagnostic radiography uses. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital detectors, and high voltage connectors for use in security and industrial inspection applications, such as airport security, cargo screening at ports and borders, and nondestructive testing and examination in various applications. Varex Imaging Corporation sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was founded in 2016 and is based in Salt Lake City, Utah.
Next Earnings
2026-01-11
Beta
0.861
Average Volume
294053
Market Cap
556001073
Last Dividend
0
CIK
0001681622
ISIN
US92214X1063
CUSIP
92214X106
CEO
Sunny S. Sanyal
Sector
Healthcare
Industry
Medical - Devices
Full Time Employees
2300
IPO Date
2017-01-23
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Should Value Investors Buy VAREX IMAGING (VREX) Stock? | Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. | Zacks Investment Research | 2026-01-09 10:40:55 |
| Varex to Participate in CJS Securities 26th Annual New Ideas for the New Year Conference | SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to present at the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference. Management will be presenting on Wednesday, January 14, 2026 at 3:50pm ET. The webcast can be accessed here or on Varex's website at www.vareximaging.com/news. About Varex Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which incl. | Business Wire | 2026-01-06 09:05:00 |
| Are Investors Undervaluing VAREX IMAGING (VREX) Right Now? | Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. | Zacks Investment Research | 2025-12-24 10:41:22 |
| Wall Street Analysts Think VAREX IMAGING (VREX) Could Surge 29.92%: Read This Before Placing a Bet | The consensus price target hints at a 29.9% upside potential for VAREX IMAGING (VREX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | Zacks Investment Research | 2025-12-16 10:56:20 |
| Should Value Investors Buy VAREX IMAGING (VREX) Stock? | Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. | Zacks Investment Research | 2025-12-08 10:41:10 |
| Should Value Investors Buy VAREX IMAGING (VREX) Stock? | Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. | Zacks Investment Research | 2025-11-20 10:40:55 |
| Varex Imaging Corporation (VREX) Q4 2025 Earnings Call Transcript | Varex Imaging Corporation ( VREX ) Q4 2025 Earnings Call November 18, 2025 5:00 PM EST Company Participants Christopher Belfiore - Director of Investor Relations Sunny Sanyal - President, CEO & Director Shubham Maheshwari - CFO & Principal Accounting Officer Conference Call Participants Suraj Kalia - Oppenheimer & Co. Inc., Research Division Lawrence Solow - CJS Securities, Inc. James Sidoti - Sidoti & Company, LLC Anderson Schock - B. Riley Securities, Inc., Research Division Presentation Operator Greetings, and welcome to the Varex Fourth Quarter Fiscal Year 2025 Earnings Conference Call and Webcast. | Seeking Alpha | 2025-11-18 19:48:49 |
| Compared to Estimates, VAREX IMAGING (VREX) Q4 Earnings: A Look at Key Metrics | While the top- and bottom-line numbers for VAREX IMAGING (VREX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. | Zacks Investment Research | 2025-11-18 18:31:07 |
| VAREX IMAGING (VREX) Q4 Earnings and Revenues Surpass Estimates | VAREX IMAGING (VREX) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.19 per share a year ago. | Zacks Investment Research | 2025-11-18 18:16:06 |
| Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025 | SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the fourth quarter and fiscal year 2025. Q4FY25 Summary Revenues $229 million GAAP gross margin 34% | Non-GAAP gross margin* 34% GAAP operating margin 9% | Non-GAAP operating margin* 10% GAAP net income $0.29 per diluted share | Non-GAAP net income* $0.37 per diluted share Cash flow from operations was $8 million FY25 Summary Revenues $845 million GAAP gross margin 34% |. | Business Wire | 2025-11-18 16:05:00 |
| Varex Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call | SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the fourth quarter and fiscal year 2025, following the close of regular trading on Tuesday, November 18, 2025. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access. | Business Wire | 2025-10-28 09:10:00 |
| Critical Comparison: VAREX IMAGING (NASDAQ:VREX) vs. Haemonetics (NYSE:HAE) | VAREX IMAGING (NASDAQ: VREX - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Insider and Institutional Ownership 99.7% of Haemonetics shares are | Defense World | 2025-10-26 02:36:24 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| ARS | 2025-12-29 | 2025-12-29 | View Filing |
| DEFA14A | 2025-12-29 | 2025-12-29 | View Filing |
| DEF 14A | 2025-12-29 | 2025-12-29 | View Filing |
| 4 | 2025-12-17 | 2025-12-17 | View Filing |
| 4 | 2025-12-17 | 2025-12-17 | View Filing |
| 4 | 2025-12-17 | 2025-12-17 | View Filing |
| 4 | 2025-12-17 | 2025-12-17 | View Filing |
| 4 | 2025-12-17 | 2025-12-17 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 10-K | 2025-11-18 | 2025-11-18 | View Filing |
| 8-K | 2025-11-18 | 2025-11-18 | View Filing |
| SC 13G/A | 2025-10-31 | 2025-10-31 | View Filing |
| 3 | 2025-10-16 | 2025-10-16 | View Filing |
| SC 13G/A | 2025-10-09 | 2025-10-09 | View Filing |
| 4 | 2025-09-22 | 2025-09-22 | View Filing |
| 8-K | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| SC 13G/A | 2025-07-03 | 2025-07-03 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| SD | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| SC 13G/A | 2025-04-17 | 2025-04-17 | View Filing |
| 8-K | 2025-04-04 | 2025-04-04 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| 4 | 2025-03-21 | 2025-03-21 | View Filing |
| S-8 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-14 | 2025-02-13 | View Filing |
| SC 13G/A | 2025-02-12 | 2025-02-12 | View Filing |
| 10-Q | 2025-02-06 | 2025-02-06 | View Filing |
| 8-K | 2025-02-06 | 2025-02-06 | View Filing |
| SC 13G/A | 2025-01-31 | 2025-01-31 | View Filing |
| SC 13G/A | 2025-01-23 | 2025-01-23 | View Filing |
| 8-K/A | 2025-01-06 | 2025-01-03 | View Filing |
| DEFA14A | 2025-01-02 | 2024-12-31 | View Filing |
| ARS | 2024-12-30 | 2024-12-30 | View Filing |
| DEFA14A | 2024-12-30 | 2024-12-30 | View Filing |
| DEF 14A | 2024-12-30 | 2024-12-30 | View Filing |
| 8-K | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| PRE 14A | 2024-12-17 | 2024-12-17 | View Filing |
| 8-K | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 10-K | 2024-11-19 | 2024-11-19 | View Filing |
| 8-K | 2024-11-19 | 2024-11-19 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G/A | 2024-11-04 | 2024-11-04 | View Filing |
| SC 13G | 2024-10-15 | 2024-10-15 | View Filing |
| SC 13G/A | 2024-10-09 | 2024-10-09 | View Filing |
| 8-K | 2024-09-11 | 2024-09-11 | View Filing |
| 4 | 2024-09-05 | 2024-09-05 | View Filing |
| 4 | 2024-08-21 | 2024-08-21 | View Filing |
| 4 | 2024-08-19 | 2024-08-19 | View Filing |
| 4 | 2024-08-14 | 2024-08-14 | View Filing |
| 4 | 2024-08-12 | 2024-08-12 | View Filing |
| 10-Q | 2024-08-01 | 2024-08-01 | View Filing |
| 8-K | 2024-08-01 | 2024-08-01 | View Filing |
| SD | 2024-05-28 | 2024-05-28 | View Filing |
| 10-Q | 2024-05-02 | 2024-05-02 | View Filing |
| 8-K | 2024-05-02 | 2024-05-02 | View Filing |
| 8-K | 2024-03-27 | 2024-03-27 | View Filing |
| 4 | 2024-03-19 | 2024-03-19 | View Filing |
| 4 | 2024-02-20 | 2024-02-20 | View Filing |
| 4 | 2024-02-20 | 2024-02-20 | View Filing |
| 4 | 2024-02-20 | 2024-02-20 | View Filing |
| 4 | 2024-02-20 | 2024-02-20 | View Filing |
| S-8 | 2024-02-16 | 2024-02-16 | View Filing |
| SC 13G | 2024-02-14 | 2024-02-14 | View Filing |
| SC 13G | 2024-02-13 | 2024-02-13 | View Filing |
| 3 | 2024-02-13 | 2024-02-13 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Keltner Channel Strategy | 25.71% | 0.99 | 276 | 0.03 | 0.1 | 24.41 |
| Bollinger Bands Strategy | 22.88% | 0.99 | 118 | 0.03 | 0.13 | 21.58 |
| RSI Overbought Strategy | 17.18% | 1.02 | 262 | 0.02 | 0.08 | 15.87 |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxxx | xxxxx | xxxx | x |
| xxxxxxxxxx | xxxxxx% | xxxx | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |